Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MK-8457
- Development stage
- Phase 1
- Lead developer
- Merck
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
MK-8457 is a potent, reversible, ATP-competitive small molecule inhibitor that targets spleen tyrosine kinase (SYK) and zeta-chain-associated protein kinase 70 (ZAP70). It was developed for the treatment of rheumatoid arthritis (RA), particularly in patients with an inadequate response to methotrexate or anti-TNF-alpha therapies. The drug demonstrated significant inhibition of immune cell activation pathways mediated by SYK and ZAP70, which are critical in B-cell receptor and T-cell receptor signaling. Preclinical studies showed efficacy in animal models of arthritis, while clinical trials indicated some efficacy in RA patients with inadequate response to methotrexate but not those who failed anti-TNF therapy. However, development was discontinued due to a high rate of serious infections observed during clinical trials[2][4][5].
02
Targets
BLK (B lymphoid tyrosine kinase)SRC (Proto-oncogene tyrosine-protein kinase Src)SYK (Spleen Tyrosine Kinase)NTRK3 (Tropomyosin receptor kinase C)ZAP70 (Zeta-chain-associated protein kinase 70)
Beyond the preview
Go deeper on MK-8457.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MK-8457.